Morgan Stanley Nrx Pharmaceuticals, Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 17, 2024
BUY
$0.29 - $0.7 $12,744 - $30,763
43,948 New
43,948 $20,000
Q1 2024

Aug 16, 2024
SELL
$0.29 - $0.7 $111 - $270
-386 Reduced 0.87%
43,948 $20,000
Q1 2024

May 15, 2024
SELL
$0.29 - $0.7 $111 - $270
-386 Reduced 0.87%
43,948 $20,000
Q4 2023

Aug 16, 2024
BUY
$0.26 - $0.47 $11,526 - $20,836
44,334 New
44,334 $20,000
Q4 2023

Feb 13, 2024
SELL
$0.26 - $0.47 $777 - $1,406
-2,992 Reduced 6.32%
44,334 $20,000
Q1 2023

May 15, 2023
SELL
$0.66 - $1.4 $1,987 - $4,216
-3,012 Reduced 5.98%
47,326 $31,000
Q4 2022

Feb 14, 2023
SELL
$0.79 - $9.19 $7,090 - $82,480
-8,975 Reduced 15.13%
50,338 $55,000
Q3 2022

Nov 14, 2022
BUY
$0.2 - $8.07 $589 - $23,790
2,948 Added 5.23%
59,313 $43,000
Q2 2022

Oct 27, 2022
BUY
$0.51 - $2.42 $2,329 - $11,054
4,568 Added 8.82%
56,365 $33,000
Q2 2022

Aug 15, 2022
BUY
$0.51 - $2.42 $2,329 - $11,054
4,568 Added 8.82%
56,365 $33,000
Q1 2022

Oct 27, 2022
SELL
$2.45 - $5.04 $11,191 - $23,022
-4,568 Reduced 8.1%
51,797 $128,000
Q1 2022

May 13, 2022
SELL
$2.45 - $5.04 $13,590 - $27,956
-5,547 Reduced 9.67%
51,797 $128,000
Q4 2021

Feb 14, 2022
BUY
$4.5 - $11.91 $73,314 - $194,037
16,292 Added 39.69%
57,344 $274,000
Q3 2021

Nov 15, 2021
BUY
$8.52 - $24.77 $349,763 - $1.02 Million
41,052 New
41,052 $381,000

Others Institutions Holding NRXP

# of Institutions
2
Shares Held
17.4K
Call Options Held
0
Put Options Held
0
View Full List

About NRX Pharmaceuticals, Inc.

NRXP Quotes by TradingView
  • Ticker NRXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,641,296
  • Market Cap $81.2M
  • Description
  • NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...
More about NRXP
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email